News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
812,635 Results
Type
Article (75431)
Company Profile (701)
Press Release (736503)
Section
Business (228685)
Career Advice (3767)
Deals (39322)
Drug Delivery (122)
Drug Development (89457)
Employer Resources (194)
FDA (17821)
Job Trends (17124)
News (389276)
Policy (38836)
Tag
Academia (2974)
Alliances (56107)
Alzheimer's disease (1396)
Approvals (17753)
Artificial intelligence (192)
Bankruptcy (394)
Best Places to Work (12594)
Biotechnology (480)
Breast cancer (218)
Cancer (1629)
Cardiovascular disease (140)
Career advice (3205)
Cell therapy (351)
Clinical research (71267)
Collaboration (614)
Compensation (318)
COVID-19 (2822)
C-suite (145)
Data (1505)
Diabetes (207)
Diagnostics (6735)
Earnings (92966)
Employer resources (167)
Events (126957)
Executive appointments (500)
FDA (18631)
Funding (544)
Gene therapy (247)
GLP-1 (743)
Government (5032)
Healthcare (20787)
Infectious disease (2928)
Inflammatory bowel disease (129)
Interviews (737)
IPO (17620)
Job creations (5020)
Job search strategy (2625)
Layoffs (501)
Legal (9901)
Lung cancer (243)
Manufacturing (244)
Medical device (14466)
Medtech (14471)
Mergers & acquisitions (21940)
Metabolic disorders (570)
Neuroscience (1797)
NextGen: Class of 2025 (7630)
Non-profit (5073)
Northern California (1911)
Obesity (325)
Opinion (252)
Patents (143)
People (63688)
Pharmaceutical (144)
Phase I (21996)
Phase II (31063)
Phase III (23433)
Pipeline (634)
Postmarket research (3295)
Preclinical (9733)
Radiopharmaceuticals (261)
Rare diseases (317)
Real estate (7183)
Regulatory (25630)
Research institute (2644)
Resumes & cover letters (589)
Southern California (1662)
Startups (4199)
United States (17781)
Vaccines (682)
Weight loss (253)
Date
Today (8)
Last 7 days (642)
Last 30 days (1967)
Last 365 days (37518)
2025 (1706)
2024 (37979)
2023 (42568)
2022 (53927)
2021 (58723)
2020 (57669)
2019 (51319)
2018 (39100)
2017 (36903)
2016 (37861)
2015 (43886)
2014 (38728)
2013 (34870)
2012 (36730)
2011 (36815)
2010 (36487)
Location
Africa (1198)
Arizona (221)
Asia (48398)
Australia (8335)
California (4460)
Canada (1573)
China (379)
Colorado (202)
Connecticut (226)
Europe (109406)
Florida (613)
Georgia (157)
Illinois (486)
Indiana (261)
Maryland (742)
Massachusetts (3552)
Michigan (205)
Minnesota (340)
New Jersey (1245)
New York (1247)
North Carolina (918)
Northern California (1911)
Ohio (163)
Pennsylvania (1026)
South America (1574)
Southern California (1662)
Texas (652)
Utah (127)
Washington State (466)
812,635 Results for "atom bioscience and pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout
Atom Bioscience, a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of the dangers of chronic gout to help mark Gout Awareness Day, May 22, 2024.
May 21, 2024
·
2 min read
Press Releases
Atom Therapeutics and China Medical System Holdings Enter Exclusive Commercialization Agreement for Lingdolinurad (ABP-671) to Treat Chronic Gout and Hyperuricemia
December 3, 2024
·
4 min read
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3
October 9, 2023
·
3 min read
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
Drug Development
Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial of a New Investigational Treatment for Chronic Gout
Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout.
April 24, 2024
·
2 min read
Press Releases
Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan
December 25, 2024
·
1 min read
Press Releases
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth
December 3, 2024
·
8 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Press Releases
Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering
December 31, 2024
·
4 min read
Press Releases
Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering
December 26, 2024
·
4 min read
1 of 81,264
Next
